As Dicerna Pharmaceuticals (DRNA) Stock Rose, Holder Longwood Capital Partners Raised Its …

… with their article: “Tracking Seth Klarman’s Baupost Group Holdings – Q2 2019 Update – Seeking Alpha” published on August 16, 2019, Finance.

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Logo

Longwood Capital Partners Llc increased its stake in Dicerna Pharmaceuticals Inc (DRNA) by 16.93% based on its latest 2019Q2 regulatory filing with the SEC. Longwood Capital Partners Llc bought 55,675 shares as the company’s stock rose 8.52% . The institutional investor held 384,500 shares of the health care company at the end of 2019Q2, valued at $6.06M, up from 328,825 at the end of the previous reported quarter. Longwood Capital Partners Llc who had been investing in Dicerna Pharmaceuticals Inc for a number of months, seems to be bullish on the $998.74M market cap company. The stock decreased 1.68% or $0.25 during the last trading session, reaching $14.61. About 249,568 shares traded. Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) has risen 9.57% since September 14, 2018 and is uptrending. It has outperformed by 9.57% the S&P500. Some Historical DRNA News: 08/03/2018 – DICERNA PHARMACEUTICALS – BELIEVES IT HAS SUFFICIENT CASH TO FUND EXECUTION OF CURRENT CLINICAL AND OPERATING PLAN THROUGH 2019; 17/04/2018 – STAT Plus: Trade secrets battle between Alnylam, Dicerna is just one of many; 09/04/2018 – Dicerna Presenting at Conference Tomorrow; 20/04/2018 – Biotech companies Alnylam, Dicerna settle trade secrets case; 20/04/2018 – DICERNA PHARMACEUTICALS INC – ALNYLAM WILL DISMISS ALL CLAIMS OF “TRADE SECRET MISAPPROPRIATION” & OTHER RELATED CLAIMS BROUGHT IN COURT AGAINST CO; 20/04/2018 – ALNYLAM REACHES SETTLEMENT PACT WITH DICERNA PHARMACEUTICALS; 08/03/2018 – DICERNA SEES SUFFICIENT CASH TO FUND DEVELOPMENT THRU 2019; 20/04/2018 – DICERNA PHARMACEUTICALS – ALNYLAM WILL DISMISS ALL CLAIMS OF “TRADE SECRET MISAPPROPRIATION” & OTHER RELATED CLAIMS BROUGHT IN COURT AGAINST CO; 19/04/2018 – DJ Dicerna Pharmaceuticals Inc, Inst Holders, 1Q 2018 (DRNA); 30/05/2018 – Dicerna Doses First Primary Hyperoxaluria Patient with DCR-PHXC in Group B Portion of PHYOX Phase 1 Clinical Trial

Manor Road Capital Partners Llc increased its stake in Liberty Global Plc (Call) (LBTYK) by 75.68% based on its latest 2019Q2 regulatory filing with the SEC. Manor Road Capital Partners Llc bought 1.40M shares as the company’s stock rose 0.89% . The hedge fund held 3.25 million shares of the television services company at the end of 2019Q2, valued at $86.22M, up from 1.85M at the end of the previous reported quarter. Manor Road Capital Partners Llc who had been investing in Liberty Global Plc (Call) for a number of months, seems to be bullish on the $20.16 billion market cap company. The stock increased 0.33% or $0.09 during the last trading session, reaching $27.51. About 4.41 million shares traded or 1.30% up from the average. Liberty Global Plc (NASDAQ:LBTYK) has declined 0.99% since September 14, 2018 and is downtrending. It has underperformed by 0.99% the S&P500. Some Historical LBTYK News: 09/05/2018 – Vodafone Group to Buy Liberty Assets in Germany, Hungary, Romania, Czech Republic; 30/05/2018 – European Commission Conditionally Approves Liberty Global’s Ziggo Buy; 23/05/2018 – Vodafone Is Said to Offer Bonds to Finance Liberty Global Deal; 23/04/2018 – Telecom Paper: Vodafone close to buying Liberty Global assets in Germany, East Europe – report; 09/05/2018 – ♫ Reuters Insider – U.S. Morning Call: Iran deal fallout; Liberty Global and Monster Beverage loses its fizz; 09/05/2018 – VODAFONE GROUP PLC VOD.L – TRANSACTION IS NOT SUBJECT TO VODAFONE OR LIBERTY GLOBAL SHAREHOLDER APPROVALS; 09/05/2018 – Vodafone challenges Deutsche Telekom with $21.8 bln Liberty deal; 09/05/2018 – Vodafone to pay $21.8 bln for Liberty assets to boost European presence; 23/03/2018 – LIBERTY GLOBAL PLC – AGREEMENT TO ACQUIRE MULTIMEDIA POLSKA S.A. HAS BEEN TERMINATED – SEC FILING; 08/05/2018 – Vodafone nears €18bn game-changing Liberty Global deal

More notable recent Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) news were published by: Nasdaq.com which released: “After-Hours Earnings Report for March 11, 2019 : ADT, COUP, SFIX, DRNA, AVD, PETQ, CCXI, LXFR, MG, OXFD, FRTA, KALA – Nasdaq” on March 11, 2019, also Finance.Yahoo.com with their article: “Here’s What Hedge Funds Think About Dicerna Pharmaceuticals Inc (DRNA) – Yahoo Finance” published on June 11, 2019, Seekingalpha.com published: “Dicerna Pharmaceuticals (DRNA) Presents At Cowen And Company 39th Annual Health Care Conference – Slideshow – Seeking Alpha” on March 12, 2019. More interesting news about Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) were released by: Seekingalpha.com and their article: “Dicerna prices follow-on common stock offering – Seeking Alpha” published on September 07, 2018 as well as Seekingalpha.com‘s news article titled: “Dicerna Pharmaceuticals (DRNA) To Present At SVB Leerink 8th Global Healthcare Conference – Slideshow – Seeking Alpha” with publication date: March 01, 2019.

Investors sentiment decreased to 1.52 in 2019 Q2. Its down 0.07, from 1.59 in 2019Q1. It is negative, as 10 investors sold DRNA shares while 21 reduced holdings. 19 funds opened positions while 28 raised stakes. 45.15 million shares or 2.31% less from 46.22 million shares in 2019Q1 were reported. Fosun Int Limited invested in 188,673 shares. 63,923 are owned by Rafferty Asset Limited Liability. Fmr Ltd Limited Liability Company invested in 0% or 667,948 shares. Northern Corporation stated it has 683,682 shares. Natl Bank Of Montreal Can, Ontario – Canada-based fund reported 4,298 shares. Legal General Grp Inc Pcl reported 0% of its portfolio in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Td Asset Mngmt has 53,480 shares. Ny State Common Retirement Fund has invested 0% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Acuta Partners Limited Liability holds 384,500 shares or 2.15% of its portfolio. Birchview Limited Partnership reported 0.43% of its portfolio in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Dafna Capital Ltd Liability reported 118,314 shares. Ra Cap Mgmt Lc holds 2.08% or 2.46 million shares in its portfolio. Blackrock holds 4.27 million shares. Voya Mngmt Ltd Liability reported 22,263 shares. 25,673 are owned by Proshare Limited Com.

Since May 29, 2019, it had 0 buys, and 1 sale for $20.00 million activity.

More notable recent Liberty Global Plc (NASDAQ:LBTYK) news were published by: Streetinsider.com which released: “Liberty Global (LBTYA) Announces Preliminary Results of Modified Dutch Auction Tender Offers – StreetInsider.com” on September 10, 2019, also Seekingalpha.com with their article: “Tracking Seth Klarman’s Baupost Group Holdings – Q2 2019 Update – Seeking Alpha” published on August 16, 2019, Finance.Yahoo.com published: “Seth Klarman’s Baupost Boosts Liberty, Reduces eBay – Yahoo Finance” on August 15, 2019. More interesting news about Liberty Global Plc (NASDAQ:LBTYK) were released by: Nasdaq.com and their article: “Vanguard FTSE All-World ex-US ETF Experiences Big Inflow – Nasdaq” published on August 20, 2019 as well as Finance.Yahoo.com‘s news article titled: “Liberty Global PLC (LBTYK) Q2 2019 Earnings Call Transcript – Yahoo Finance” with publication date: August 09, 2019.

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Related Posts:

  • No Related Posts

Baillie Gifford & Co. Grows Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Millennium Management LLC acquired a new stake in Alnylam Pharmaceuticals in the 4th quarter valued at $829,000. Dimensional Fund Advisors LP …

Alnylam Pharmaceuticals logoBaillie Gifford & Co. lifted its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 9.3% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,213,470 shares of the biopharmaceutical company’s stock after purchasing an additional 528,966 shares during the quarter. Baillie Gifford & Co. owned 5.83% of Alnylam Pharmaceuticals worth $450,850,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in ALNY. Millennium Management LLC acquired a new stake in Alnylam Pharmaceuticals in the 4th quarter valued at $829,000. Dimensional Fund Advisors LP increased its stake in shares of Alnylam Pharmaceuticals by 41.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 225,148 shares of the biopharmaceutical company’s stock worth $16,412,000 after purchasing an additional 66,253 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 3.9% during the 4th quarter. Geode Capital Management LLC now owns 915,533 shares of the biopharmaceutical company’s stock worth $66,708,000 after buying an additional 34,770 shares during the period. Meeder Asset Management Inc. boosted its holdings in shares of Alnylam Pharmaceuticals by 332.9% during the 1st quarter. Meeder Asset Management Inc. now owns 342 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 263 shares during the period. Finally, Bank of Montreal Can boosted its holdings in shares of Alnylam Pharmaceuticals by 6.5% during the 1st quarter. Bank of Montreal Can now owns 73,730 shares of the biopharmaceutical company’s stock worth $6,890,000 after buying an additional 4,482 shares during the period. 94.26% of the stock is currently owned by institutional investors.

A number of analysts have recently weighed in on the stock. Morgan Stanley cut their price target on shares of Alnylam Pharmaceuticals from $126.00 to $124.00 and set an “overweight” rating for the company in a report on Wednesday, August 7th. UBS Group upped their price objective on shares of Alnylam Pharmaceuticals from $95.00 to $96.00 and gave the stock a “neutral” rating in a research report on Wednesday, September 4th. Stifel Nicolaus set a $116.00 price target on shares of Alnylam Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Cowen decreased their price objective on shares of Alnylam Pharmaceuticals from $147.00 to $120.00 and set an “outperform” rating for the company in a research report on Wednesday, August 7th. Finally, Goldman Sachs Group reiterated a “neutral” rating and set a $80.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Thursday, May 23rd. Six research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $116.13.

Shares of Alnylam Pharmaceuticals stock opened at $86.17 on Thursday. The company has a debt-to-equity ratio of 0.17, a current ratio of 6.28 and a quick ratio of 6.16. Alnylam Pharmaceuticals, Inc. has a 1 year low of $60.27 and a 1 year high of $99.73. The company has a 50 day simple moving average of $79.70 and a two-hundred day simple moving average of $78.88. The firm has a market cap of $9.45 billion, a PE ratio of -11.38 and a beta of 2.35.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($2.02) EPS for the quarter, topping the consensus estimate of ($2.06) by $0.04. The company had revenue of $38.20 million for the quarter, compared to the consensus estimate of $42.24 million. Alnylam Pharmaceuticals had a negative net margin of 848.70% and a negative return on equity of 56.42%. The firm’s revenue for the quarter was up 27.8% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.61) earnings per share. As a group, research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -8.21 earnings per share for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company’s pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases.

Featured Story: Does the Dogs of the Dow strategy work?

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Allianz Asset Management GmbH Sells 19274 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ …

BlackRock Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 4.6% in the first quarter. BlackRock Inc. now owns 6,428,127 shares of …

Alnylam Pharmaceuticals logoAllianz Asset Management GmbH decreased its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 15.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 104,653 shares of the biopharmaceutical company’s stock after selling 19,274 shares during the quarter. Allianz Asset Management GmbH owned about 0.10% of Alnylam Pharmaceuticals worth $7,593,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also modified their holdings of the business. FMR LLC increased its holdings in shares of Alnylam Pharmaceuticals by 5.2% in the first quarter. FMR LLC now owns 15,945,666 shares of the biopharmaceutical company’s stock worth $1,490,122,000 after purchasing an additional 791,113 shares during the period. BlackRock Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 4.6% in the first quarter. BlackRock Inc. now owns 6,428,127 shares of the biopharmaceutical company’s stock worth $600,707,000 after purchasing an additional 282,322 shares during the period. Segantii Capital Management Ltd bought a new position in shares of Alnylam Pharmaceuticals in the second quarter worth $7,111,000. Candriam Luxembourg S.C.A. increased its holdings in shares of Alnylam Pharmaceuticals by 34.1% in the second quarter. Candriam Luxembourg S.C.A. now owns 381,724 shares of the biopharmaceutical company’s stock worth $27,576,000 after purchasing an additional 97,023 shares during the period. Finally, Sector Gamma AS bought a new position in shares of Alnylam Pharmaceuticals in the second quarter worth $5,217,000. 87.30% of the stock is currently owned by institutional investors and hedge funds.

ALNY opened at $82.33 on Thursday. The company has a debt-to-equity ratio of 0.17, a current ratio of 6.28 and a quick ratio of 6.16. Alnylam Pharmaceuticals, Inc. has a 52 week low of $60.27 and a 52 week high of $119.99. The business’s fifty day simple moving average is $78.73 and its 200 day simple moving average is $78.81.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($2.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.06) by $0.04. Alnylam Pharmaceuticals had a negative net margin of 848.70% and a negative return on equity of 56.42%. The business had revenue of $38.20 million during the quarter, compared to analyst estimates of $42.24 million. During the same period in the prior year, the business posted ($1.61) earnings per share. The company’s revenue was up 27.8% on a year-over-year basis. As a group, analysts expect that Alnylam Pharmaceuticals, Inc. will post -8.21 EPS for the current fiscal year.

Several research firms have recently weighed in on ALNY. ValuEngine raised shares of Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 1st. Morgan Stanley reduced their target price on Alnylam Pharmaceuticals from $126.00 to $124.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 7th. Goldman Sachs Group reissued a “neutral” rating and issued a $80.00 target price on shares of Alnylam Pharmaceuticals in a research note on Thursday, May 23rd. Zacks Investment Research cut Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, May 8th. Finally, BidaskClub raised Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, August 23rd. Five investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $116.13.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company’s pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases.

Read More: Coverage Ratio

Want to see what other hedge funds are holding ALNY?Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

In Wake of Terminations, Pharma Leaders Decry Actions That Will Limit Collaborations with …

… and Decibel Therapeutics, as well as top investor groups like Atlas Venture and academic institutions like Massachusetts Institute of Technology, …

chess pieces with china and us flags on them

Leaders from across the pharmaceutical industry are decrying negative actions taken by government agencies and universities against Chinese researchers in the United States. Those negative actions threaten the United States’ position as a leader in biomedical science, they claim in an open letter.

The concerns were outlined in a letter signed by top executives from noted pharma companies like Ovid Therapeutics, Alnylam Pharmaceuticals, Acorda Therapeutics and Decibel Therapeutics, as well as top investor groups like Atlas Venture and academic institutions like Massachusetts Institute of Technology, Harvard Universityand Northwestern University. The letter points to a number of actions taken by research institutions and universities against Chinese researchers or U.S. scientists of Chinese ancestry. Earlier this year there were two noted incidents of ethnically-Chinese scientists being caught up in concerns raised by the Federal Bureau of Investigation and the National Institutes of Health regarding intellectual property theft. Chinese scientists at M.D. Anderson were terminated over concerns of intellectual property theft in April, then in May, a husband and wife neuroscience research team was terminated at Emory University after they were accused of failing to disclose ties to China that included financial funding. A 2017 report issued by the FBI noted that that intellectual-property theft by China costs the U.S. as much as $600 billion annually.

Click to create a jobseeker profile

With those incidents in mind, the signers of the letter said incidents like those noted above have created “a climate of fear and uncertainty in our biomedical communities.” The letter signers did not dismiss the dangers of intellectual property theft by foreign agents. In fact, in the letter, they urged that those who engage in such activities be prosecuted. But, they said actions that limit collaboration between Chinese and American scientists and companies would be deleterious to national interests. So too, would limitations on American residents of Chinese origin receiving government research funding or being employed by the NIH, the letter said. Only through collaboration with an international cadre of scientists and researchers will the wars against disease be won, the letter said. Those collaborations are important as the scientific community takes on diseases such as cancers, immune diseases, Alzheimer’s disease, infections and more.

“If we are to prevail in humanity’s common quest to conquer disease, our surest route is to include any person able to contribute, regardless of country of origin, religion, race, gender or other identity. The U.S. biomedical community stands for the principles of diversity and unity embedded in the founding principles of our country, without which our leadership indeed will soon be lost,” the letter states.

The letter further points to the necessity of an open exchange of ideas within the scientific community to attack these diseases. By turning out foreign-born scientists, the signatories of the letter said it will only weaken the research that could benefit from global insight. Citing former President Ronald Reagan, the letter writers said if the doors of America are closed to foreign scientists over these kinds of fears, then the U.S. will lose its position as the leader in biomedical science.

“An atmosphere of intimidation will encourage many outstanding scientists of Chinese origin to leave the US or never to come. In addition, scientists from other countries who are working in the U.S. cannot fail to get the message that they may well be next,” the letter warns.

Related Posts:

  • No Related Posts

Should You Buy CrowdStrike Holdings, Inc. (CRWD) or Alnylam Pharmaceuticals, Inc. (ALNY)?

CrowdStrike Holdings, Inc. (NASDAQ:CRWD) shares are up more than 57.81% this year and recently increased 2.76% or $2.46 to settle at $91.53.

CrowdStrike Holdings, Inc. (NASDAQ:CRWD) shares are up more than 57.81% this year and recently increased 2.76% or $2.46 to settle at $91.53. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), on the other hand, is up 3.36% year to date as of 08/01/2019. It currently trades at $75.36 and has returned 1.65% during the past week.

CrowdStrike Holdings, Inc. (NASDAQ:CRWD) and Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) are the two most active stocks in the Security Software & Services industry based on today’s trading volumes. Investor interest in the two stocks is clearly very high, but which is the better investment? To answer this question, we will compare the two companies across growth, profitability, risk, and valuation metrics, and also examine their analyst ratings and insider activity trends.

Growth

The ability to consistently grow earnings at a high compound rate is a defining characteristic of the best companies for long-term investment. Comparatively, ALNY is expected to grow at a 46.09% annual rate. All else equal, ALNY’s higher growth rate would imply a greater potential for capital appreciation.

Profitability and Returns

A high growth rate isn’t necessarily valuable to investors. In fact, companies that overinvest in low return projects just to achieve a high growth rate can actually destroy shareholder value. Profitability and returns are a measure of the quality of a company’s business and its growth opportunities. We’ll use Return on Investment (ROI) to measure this. CRWD’s ROI is 28.30% while ALNY has a ROI of -59.70%. The interpretation is that CRWD’s business generates a higher return on investment than ALNY’s.

Cash Flow

Earnings don’t always accurately reflect the amount of cash that a company brings in. On a percent-of-sales basis, CRWD’s free cash flow was 0% while ALNY converted -0.31% of its revenues into cash flow. This means that, for a given level of sales, CRWD is able to generate more free cash flow for investors.

Liquidity and Financial Risk

Analysts look at liquidity and leverage ratios to assess how easily a company can cover its liabilities. CRWD has a current ratio of 1.00 compared to 9.30 for ALNY. This means that ALNY can more easily cover its most immediate liabilities over the next twelve months.

Valuation

CRWD trades at a P/S of 62.43, compared to a P/B of 5.13, and a P/S of 94.09 for ALNY. Given that earnings are what matter most to investors, analysts tend to place a greater weight on the P/E.

Analyst Price Targets and Opinions

A cheap stock isn’t a good investment if the stock is priced accurately. To get a sense of “value” we must compare the current price to some measure of intrinsic value such as a price target. CRWD is currently priced at a 3.94% to its one-year price target of 88.06. Comparatively, ALNY is -38.03% relative to its price target of 121.61. This suggests that ALNY is the better investment over the next year.

Insider Activity and Investor Sentiment

Short interest is another tool that analysts use to gauge investor sentiment. It represents the percentage of a stock’s tradable shares that are being shorted. CRWD has a short ratio of 0.57 compared to a short interest of 5.61 for ALNY. This implies that the market is currently less bearish on the outlook for CRWD.

Summary

CrowdStrike Holdings, Inc. (NASDAQ:CRWD) beats Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) on a total of 8 of the 14 factors compared between the two stocks. CRWD generates a higher return on investment, has higher cash flow per share, has a higher cash conversion rate and has lower financial risk. In terms of valuation, CRWD is the cheaper of the two stocks on book value and sales basis, Finally, CRWD has better sentiment signals based on short interest.

Related Posts:

  • No Related Posts